TY - JOUR
T1 - Enhancing patient stratification methods for medication review during acute admissions
AU - Westberg Strejby Christensen, Louise
AU - Juul-Larsen, Helle Gybel
AU - Rasmussen, Line Jee Hartmann
AU - Iversen, Esben
AU - Dalhoff, Kim Peder
AU - Andersen, Ove
AU - Houlind, Morten Baltzer
N1 - © 2025 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
PY - 2025/11
Y1 - 2025/11
N2 - Medication review in the hospital is an effective tool for identifying inappropriate prescribing, but not every patient can receive one due to resource constraints. Thus, it is important to identify patients who stand to benefit most from medication review. Patients are typically identified for medication review based on number of medications and age, but this may not be the most efficient strategy for identifying patients at high risk of future adverse clinical outcomes. In this exploratory study of 27 873 acutely admitted medical patients (≥18 years) at Copenhagen University Hospital Hvidovre, Denmark, we investigated whether other clinical factors could improve the prediction of adverse clinical outcomes and, therefore, be incorporated into patient stratification for medication review. The outcomes of interest were acute readmission or mortality within 90 days post-discharge. Medication risk score (MERIS), renal function and anticholinergic cognitive burden did not improve prediction of adverse clinical outcomes compared to number of medications and age. However, addition of a frailty index based on routine biomarkers (FI-OutRef) or plasma soluble urokinase plasminogen activator receptor (suPAR) did improve prediction of outcomes. Use of these practical proxies of disease burden may improve the identification of acutely hospitalized patients who would benefit most from a medication review.
AB - Medication review in the hospital is an effective tool for identifying inappropriate prescribing, but not every patient can receive one due to resource constraints. Thus, it is important to identify patients who stand to benefit most from medication review. Patients are typically identified for medication review based on number of medications and age, but this may not be the most efficient strategy for identifying patients at high risk of future adverse clinical outcomes. In this exploratory study of 27 873 acutely admitted medical patients (≥18 years) at Copenhagen University Hospital Hvidovre, Denmark, we investigated whether other clinical factors could improve the prediction of adverse clinical outcomes and, therefore, be incorporated into patient stratification for medication review. The outcomes of interest were acute readmission or mortality within 90 days post-discharge. Medication risk score (MERIS), renal function and anticholinergic cognitive burden did not improve prediction of adverse clinical outcomes compared to number of medications and age. However, addition of a frailty index based on routine biomarkers (FI-OutRef) or plasma soluble urokinase plasminogen activator receptor (suPAR) did improve prediction of outcomes. Use of these practical proxies of disease burden may improve the identification of acutely hospitalized patients who would benefit most from a medication review.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Biomarkers/blood
KW - Denmark/epidemiology
KW - Female
KW - Hospitalization/statistics & numerical data
KW - Humans
KW - Inappropriate Prescribing/prevention & control
KW - Male
KW - Medication Reconciliation/methods
KW - Middle Aged
KW - Patient Admission
KW - Patient Readmission/statistics & numerical data
KW - Risk Assessment/methods
UR - https://www.scopus.com/pages/publications/105014748182
U2 - 10.1002/bcp.70254
DO - 10.1002/bcp.70254
M3 - Journal article
C2 - 40883976
SN - 0306-5251
VL - 91
SP - 3279
EP - 3287
JO - British Journal of Clinical Pharmacology
JF - British Journal of Clinical Pharmacology
IS - 11
ER -